PA8814001A1 - Profármacos de péptidos basados en ésteres - Google Patents
Profármacos de péptidos basados en ésteresInfo
- Publication number
- PA8814001A1 PA8814001A1 PA20098814001A PA8814001A PA8814001A1 PA 8814001 A1 PA8814001 A1 PA 8814001A1 PA 20098814001 A PA20098814001 A PA 20098814001A PA 8814001 A PA8814001 A PA 8814001A PA 8814001 A1 PA8814001 A1 PA 8814001A1
- Authority
- PA
- Panama
- Prior art keywords
- hours
- propharms
- peptid
- esters
- bioactive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
SE PROVEEN FORMULACIONES PROFARMACOLÓGICAS POLIPÉPTIDOS BIOACTIVOS,EN DONDE EL POLIPÉPTIDO BIOACTIVO FUE MODIFICADO POR LA LIGACIÓN DE UN DIPÉPTIDO CON EL POLIPÉPTIDO BIOACTIVO A TRAVÉS DE UN ENLACE ÉSTER.LOS PROFÁRMACOS REVELADOS EN LA PRESENTE EN ALGUNAS FORMAS DE REALIZACIÓN TIENEN VIDAS MEDIAS EXTENDIDAS DE AL MENOS 1,5 HORAS (POR EJEMPLO,DE LA MENOS 10 HORAS)Y MÁS TÍPICAMENTE,MAYORES QUE 20 HORAS Y MENORES QUE 70 HORAS Y SE CONVIERTEN EN LA FORMA ACTIVA EN CONDICIONES FISIOLÓGICAS A TRAVÉS DE UNA REACCIÓN NO ENZIMÁTICA MANEJADA POR INESTABILIDAD QUÍMICA.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2467208P | 2008-01-30 | 2008-01-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
PA8814001A1 true PA8814001A1 (es) | 2009-09-17 |
Family
ID=40952419
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PA20098814001A PA8814001A1 (es) | 2008-01-30 | 2009-01-29 | Profármacos de péptidos basados en ésteres |
Country Status (12)
Country | Link |
---|---|
US (3) | US20110065633A1 (es) |
EP (1) | EP2249853A4 (es) |
JP (1) | JP2011511778A (es) |
CN (1) | CN101983066B (es) |
AR (1) | AR073335A1 (es) |
AU (1) | AU2009210570B2 (es) |
CA (1) | CA2713348C (es) |
CL (1) | CL2009000202A1 (es) |
PA (1) | PA8814001A1 (es) |
PE (1) | PE20091440A1 (es) |
TW (1) | TW200938225A (es) |
WO (1) | WO2009099763A1 (es) |
Families Citing this family (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2572952T3 (es) | 2005-11-07 | 2016-06-03 | Indiana University Research And Technology Corporation | Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas |
WO2008086086A2 (en) | 2007-01-05 | 2008-07-17 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological ph buffers |
CA2677932A1 (en) | 2007-02-15 | 2008-08-21 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
MX2010004298A (es) * | 2007-10-30 | 2010-05-03 | Univ Indiana Res & Tech Corp | Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1. |
CA2707861A1 (en) | 2007-10-30 | 2009-05-07 | Indiana University Research And Technology Corporation | Glucagon antagonists |
WO2009099763A1 (en) | 2008-01-30 | 2009-08-13 | Indiana University Research And Technology Corporation | Ester-based peptide prodrugs |
US8450270B2 (en) * | 2008-06-17 | 2013-05-28 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers |
CN102105159B (zh) * | 2008-06-17 | 2015-07-08 | 印第安纳大学研究及科技有限公司 | 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症 |
PE20100255A1 (es) | 2008-06-17 | 2010-04-25 | Univ Indiana Res & Tech Corp | Co-agonistas del receptor de glucagon/glp-1 |
AU2009335711A1 (en) * | 2008-12-19 | 2010-07-15 | Indiana University Research And Technology Corporation | Dipeptide linked medicinal agents |
EP2376521B1 (en) * | 2008-12-19 | 2016-04-13 | Indiana University Research and Technology Corporation | Amide-based insulin prodrugs |
BRPI0922969A2 (pt) * | 2008-12-19 | 2019-09-24 | Univ Indiana Res & Tech Corp | pró-farmaco de amida baseado na superfamília de glucagon peptídeo. |
CN102256992B (zh) | 2008-12-19 | 2015-04-22 | 印第安纳大学研究及科技有限公司 | 胰岛素类似物 |
IN2012DN00377A (es) | 2009-06-16 | 2015-08-21 | Univ Indiana Res & Tech Corp | |
EP2512503A4 (en) | 2009-12-18 | 2013-08-21 | Univ Indiana Res & Tech Corp | COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR |
EP2525829A1 (en) | 2010-01-22 | 2012-11-28 | Ascendis Pharma A/S | Dipeptide-based prodrug linkers for aromatic amine-containing drugs |
EP2525830B1 (en) | 2010-01-22 | 2016-05-11 | Ascendis Pharma A/S | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
MX2012008603A (es) | 2010-01-27 | 2013-01-25 | Univ Indiana Res & Tech Corp | Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad. |
CA2797089A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting g protein-coupled receptor activity |
ES2661228T3 (es) | 2010-05-13 | 2018-03-28 | Indiana University Research And Technology Corporation | Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona |
WO2011159895A2 (en) | 2010-06-16 | 2011-12-22 | Indiana University Research And Technology Corporation | Single chain insulin agonists exhibiting high activity at the insulin receptor |
JP5912112B2 (ja) * | 2010-06-24 | 2016-04-27 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | アミド系インスリンプロドラッグ |
WO2011163460A1 (en) * | 2010-06-24 | 2011-12-29 | Indiana University Research And Technology Corporation | Yl-based insulin-like growth factors exhibiting high activity at the insulin receptor |
RU2580317C2 (ru) * | 2010-06-24 | 2016-04-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов |
KR20130083843A (ko) * | 2010-06-24 | 2013-07-23 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 디펩티드 연결된 약제 |
US9023986B2 (en) | 2010-10-25 | 2015-05-05 | Hoffmann-La Roche Inc. | Glucose-dependent insulinotropic peptide analogs |
JP5894174B2 (ja) | 2010-11-03 | 2016-03-23 | アレコー リミテッド | グルカゴンを含む新規組成物 |
BR112013015861A2 (pt) | 2010-12-22 | 2018-06-05 | Marcadia Biotech Inc | métodos para reduzir ganho de peso ou induzir perda de peso, e para tratar hiperglicemia, reduzir níveis de glicose no sangue, ou normalizar níveis de glicose no sangue. |
WO2012088116A2 (en) | 2010-12-22 | 2012-06-28 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
EP3878859B1 (en) | 2011-06-10 | 2023-11-01 | Hanmi Science Co., Ltd. | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same |
WO2012173422A1 (en) | 2011-06-17 | 2012-12-20 | Hanmi Science Co., Ltd. | A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof |
BR112013032717A2 (pt) | 2011-06-22 | 2017-01-24 | Univ Indiana Res & Tech Corp | coagonistas do receptor de glucagon/glp-1 |
DK2723367T3 (en) | 2011-06-22 | 2017-07-17 | Univ Indiana Res & Tech Corp | Glucagon / GLP-1 receptor-CO-AGONISTS |
EP2729493B1 (en) | 2011-07-04 | 2020-06-10 | IP2IPO Innovations Limited | Novel compounds and their effects on feeding behaviour |
EP2741744A1 (en) * | 2011-08-12 | 2014-06-18 | Ascendis Pharma A/S | Carrier-linked prodrugs having reversible carboxylic ester linkages |
JP6352806B2 (ja) | 2011-09-23 | 2018-07-04 | ノヴォ ノルディスク アー/エス | 新規のグルカゴン類似体 |
KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
WO2013074910A1 (en) | 2011-11-17 | 2013-05-23 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting glucocorticoid receptor activity |
EP2793932B1 (en) | 2011-12-20 | 2018-10-03 | Indiana University Research and Technology Corporation | Ctp-based insulin analogs for treatment of diabetes |
ES2810153T3 (es) * | 2012-03-01 | 2021-03-08 | Novo Nordisk As | Profármacos de GLP-1 |
TWI599575B (zh) | 2012-06-21 | 2017-09-21 | 印第安納大學科技研究公司 | 表現gip受體活性之胰高血糖素類似物 |
KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
EP3395358B1 (en) | 2012-09-26 | 2019-11-06 | Indiana University Research and Technology Corporation | Insulin analog dimers |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
EA031852B1 (ru) | 2012-11-06 | 2019-03-29 | Ханми Фарм. Ко., Лтд. | Жидкая композиция белкового конъюгата, содержащего оксинтомодулин и фрагмент иммуноглобулина |
EP2925345B1 (en) | 2012-12-03 | 2018-09-05 | Merck Sharp & Dohme Corp. | Method for making o-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues |
US10421795B2 (en) | 2012-12-17 | 2019-09-24 | Merck Sharp & Dohme Corp. | Process for purifying insulin and analogues thereof |
AR094180A1 (es) | 2012-12-21 | 2015-07-15 | Sanofi Sa | Derivados de exendina-4 |
JP6538645B2 (ja) | 2013-03-14 | 2019-07-03 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | インスリン‐インクレチン複合物 |
CN105307672B (zh) | 2013-04-18 | 2021-01-05 | 诺和诺德股份有限公司 | 用于医学用途的稳定、延长的glp-1/胰高血糖素受体共激动剂 |
MX366852B (es) | 2013-10-04 | 2019-07-25 | Merck Sharp & Dohme | Conjugados de insulina sensibles a glucosa. |
WO2015084694A2 (en) | 2013-12-04 | 2015-06-11 | Merck Sharp & Dohme Corp. | Method for preparing crystalline insulin |
WO2015081891A1 (en) * | 2013-12-06 | 2015-06-11 | Baikang (Suzhou) Co., Ltd | Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs |
EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
AR098615A1 (es) * | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Péptido para el tratamiento de hipoglicemia severa |
AR098616A1 (es) | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Péptido para el tratamiento de hipoglicemia severa |
EP3116531B1 (en) | 2014-03-14 | 2021-10-20 | Merck Sharp & Dohme Corp. | Purifying insulin using cation exchange and reverse phase chromatography in the presence of an organic modifier and elevated temperature |
EA201691795A1 (ru) * | 2014-03-31 | 2017-03-31 | Ханми Фарм. Ко., Лтд. | Способ улучшения растворимости белка и пептида за счет использования связывания с фрагментом fc иммуноглобулина |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
JP2017525656A (ja) | 2014-06-04 | 2017-09-07 | ノヴォ ノルディスク アー/エス | 医療用のglp−1/グルカゴン受容体コアゴニスト |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
EP3171888B1 (en) | 2014-07-21 | 2022-12-28 | Merck Sharp & Dohme LLC | Chromatography process for purification of inlsulin and insulin analogs |
TWI802396B (zh) | 2014-09-16 | 2023-05-11 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
WO2016049174A1 (en) | 2014-09-24 | 2016-03-31 | Indiana University Research And Technology Corporation | Lipidated amide-based insulin prodrugs |
US10232020B2 (en) | 2014-09-24 | 2019-03-19 | Indiana University Research And Technology Corporation | Incretin-insulin conjugates |
CA3093383A1 (en) | 2014-10-24 | 2016-04-28 | Merck Sharp & Dohme Corp. | Co-agonists of the glucagon and glp-1 receptors |
US20170355743A1 (en) | 2014-11-21 | 2017-12-14 | Merck Sharp & Dohme Corp. | Insulin receptor partial agonists |
KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
PE20230304A1 (es) | 2014-12-30 | 2023-02-13 | Hanmi Pharm Ind Co Ltd | Derivados de glucagon como agentes hipoglucemicos y antiobesidad |
EP3268384B1 (en) | 2015-03-10 | 2021-11-03 | Merck Sharp & Dohme Corp. | Process for preparing recombinant insulin using microfiltration |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
DK3322437T3 (da) | 2015-06-30 | 2024-03-25 | Hanmi Pharmaceutical Co Ltd | Glukagonderivat og en sammensætning omfattende et langtidsvirkende konjugat af samme |
AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
US10745457B2 (en) | 2015-09-02 | 2020-08-18 | Merck Sharp & Dohme Corp. | Process for obtaining insulin with correctly formed disulfide bonds |
TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
AU2016382394B2 (en) | 2015-12-31 | 2019-07-04 | Hanmi Pharm. Co., Ltd. | Long-acting conjugate of triple glucagon/GLP-1/GIP receptor agonist |
CA3021231A1 (en) * | 2016-04-19 | 2017-10-26 | Griffon Pharmaceuticals Inc. | Pegylated bioactive peptides and uses thereof |
EP3448417A4 (en) | 2016-04-26 | 2019-12-11 | Merck Sharp & Dohme Corp. | SOUND CONJUGATES OF INSULIN-INCRETIN |
KR102449167B1 (ko) * | 2016-05-06 | 2022-09-28 | 파세비오 파마수티컬스 인코포레이티드 | 제어된 지속 방출을 위한 elp 융합 단백질 |
EP3463429A4 (en) | 2016-05-24 | 2020-07-22 | Merck Sharp & Dohme Corp. | PARTIAL INSULIN RECEPTOR AGONISTS AND GLP-1 ANALOGUES |
WO2017205309A1 (en) | 2016-05-25 | 2017-11-30 | Merck Sharp & Dohme Corp. | Insulin receptor partial agonists |
GB201611077D0 (en) | 2016-06-24 | 2016-08-10 | Arecor Ltd | Novel composition |
JP7208020B2 (ja) | 2016-06-29 | 2023-01-18 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン誘導体、その結合体、及びそれを含む組成物、並びにその治療的用途 |
EP3272877A1 (en) | 2016-07-18 | 2018-01-24 | ETH Zurich | B-cell-mimetic cells |
CN109563487A (zh) | 2016-07-18 | 2019-04-02 | 苏黎士联邦理工大学 | β细胞拟似细胞 |
SI3570844T1 (sl) | 2017-01-20 | 2024-01-31 | Arcus Biosciences, Inc. | Azolopirimidin za zdravljenje z rakom povezanih motenj |
WO2018175272A1 (en) | 2017-03-23 | 2018-09-27 | Merck Sharp & Dohme Corp. | Glucose responsive insulin comprising a tri-valent sugar cluster for treatment of diabetes |
ES2951809T3 (es) | 2017-05-17 | 2023-10-25 | Arcus Biosciences Inc | Derivados de quinazolina-pirazol para el tratamiento de trastornos relacionados con el cáncer |
CA3071611A1 (en) * | 2017-07-31 | 2019-02-07 | The Trustees Of Indiana University | Modified ddah polypeptides comprising a pharmacokinetic enhancing moiety, improved pharmacology and their uses |
CN111621014B (zh) * | 2019-02-28 | 2022-09-30 | 北京大学 | 基于羟脯氨酸的聚合物及其制备方法和解聚方法 |
CN109721653B (zh) * | 2019-03-05 | 2023-02-03 | 嘉兴学院 | 一种胰高血糖素样肽-1片段类似物及其应用 |
IL295569A (en) | 2020-03-19 | 2022-10-01 | Arcus Biosciences Inc | Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha |
US20230279054A1 (en) * | 2020-09-25 | 2023-09-07 | University Of Washington | De novo designed mixed chirality peptide macrocycles with internal symmetry |
CN114437181B (zh) * | 2022-01-25 | 2023-03-24 | 深圳深创生物药业有限公司 | 一种glp-1r/gcgr/gipr三重受体激动剂及其应用 |
Family Cites Families (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3740385A (en) | 1970-05-07 | 1973-06-19 | M Ondetti | N-terminal derivatives of secretin |
US4275152A (en) * | 1977-02-03 | 1981-06-23 | Eastman Kodak Company | Hydrolysis of protein-bound cholesterol esters |
DK119785D0 (da) * | 1985-03-15 | 1985-03-15 | Nordisk Gentofte | Insulinpraeparat |
PT83613B (en) | 1985-10-28 | 1988-11-21 | Lilly Co Eli | Process for the selective chemical removal of a protein amino-terminal residue |
US4741897A (en) | 1986-07-08 | 1988-05-03 | Baxter Travenol | Thyroxine analogs and reagents for thyroid hormone assays |
US4876242A (en) | 1987-09-21 | 1989-10-24 | Merck & Co., Inc. | Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast |
GB8728561D0 (en) | 1987-12-07 | 1988-01-13 | Glaxo Group Ltd | Chemical compounds |
US5514646A (en) | 1989-02-09 | 1996-05-07 | Chance; Ronald E. | Insulin analogs modified at position 29 of the B chain |
JPH04504416A (ja) * | 1989-02-17 | 1992-08-06 | コセルコ・ミモトープス・ピィ・ティ・ワイ.エル・ティ・ディ. | ペプチドの使用方法と合成方法 |
US6225449B1 (en) | 1991-10-04 | 2001-05-01 | Washington University | Hormone analogs with multiple CTP extensions |
HU210142B (en) | 1989-04-20 | 1995-02-28 | Sinai School Medicine | Process for producing hepatospecific insulin-analogues and pharmaceutical compositions containing them |
US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
WO1991011457A1 (en) | 1990-01-24 | 1991-08-08 | Buckley Douglas I | Glp-1 analogs useful for diabetes treatment |
US5510459A (en) * | 1991-01-17 | 1996-04-23 | Zymogenetics, Inc. | Glucagon antagonists |
US5268453A (en) | 1991-08-08 | 1993-12-07 | Scios Inc. | Tissue-selective insulin analogs |
CA2157767A1 (en) | 1993-03-09 | 1994-09-15 | Elaine M. Brate | Genetically engineered enzymes and their conjugates for diagnostic assays |
US5359030A (en) * | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
US5480867A (en) * | 1993-12-29 | 1996-01-02 | The Rockefeller University | Glucagon analogs with serine replacements |
US5512549A (en) * | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
US5869602A (en) * | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
US6476290B1 (en) | 1995-04-19 | 2002-11-05 | Dalhousie University | Transgenic tilapia comprising a humanized insulin gene |
IL118127A0 (en) | 1995-05-05 | 1996-09-12 | Lilly Co Eli | Single chain insulin with high bioactivity |
US6180767B1 (en) * | 1996-01-11 | 2001-01-30 | Thomas Jefferson University | Peptide nucleic acid conjugates |
NZ334595A (en) | 1996-09-09 | 2000-08-25 | Zealand Pharmaceuticals As | Peptide prodrugs containing an alpha-hydroxyacid linker that have increased stability against enzymatic cleavage |
UA65549C2 (uk) * | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
HUP0100928A3 (en) | 1998-02-23 | 2001-11-28 | Neurocrine Biosciences Inc San | Methods for treatment of diabetes using peptide analogues of insulin |
WO1999046283A1 (en) | 1998-03-09 | 1999-09-16 | Zealand Pharmaceuticals A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
US6875741B2 (en) | 1998-09-02 | 2005-04-05 | Renuka Pillutla | Insulin and IGF-1 receptor agonists and antagonists |
US20030236190A1 (en) * | 1998-09-02 | 2003-12-25 | Renuka Pillutla | Isulin and IGF-1 receptor agonists and antagonists |
DE19908041A1 (de) | 1999-02-24 | 2000-08-31 | Hoecker Hartwig | Kovalent verbrückte Insulindimere |
ES2225107T3 (es) | 1999-03-29 | 2005-03-16 | Uutech Limited | Analogos del peptido inhibidor gastrico y su uso para el tratamiento de la diabetes. |
US6746853B1 (en) | 1999-05-19 | 2004-06-08 | Xencor, Inc. | Proteins with insulin-like activity useful in the treatment of diabetes |
AUPQ661800A0 (en) * | 2000-03-31 | 2000-05-04 | Metabolic Pharmaceuticals Limited | Insulin-potentiating compounds |
US6677136B2 (en) * | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
US20030021795A1 (en) * | 2000-06-14 | 2003-01-30 | Houston Michael E. | Use of coiled-coil structural scaffold to generate structure-specific peptides |
EP1305338A2 (en) | 2000-08-02 | 2003-05-02 | Theratechnologies Inc. | Modified peptides with increased potency |
GB2382346B (en) * | 2000-08-04 | 2004-08-11 | Dmi Biosciences Inc | Method of synthesizing diketopiperazines |
US7052686B2 (en) * | 2000-09-29 | 2006-05-30 | Schering Corporation | Pegylated interleukin-10 |
KR100449454B1 (ko) | 2000-10-02 | 2004-09-21 | 이현철 | 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터 |
KR101229995B1 (ko) | 2000-12-11 | 2013-02-06 | 씨제이 주식회사 | 생체내 에리스로포이에틴 활성이 증진된 융합단백질 |
EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
MXPA03009566A (es) * | 2001-04-19 | 2004-12-06 | Scripps Research Inst | Metodos y composicion para la produccion de pares trna-aminoaciltrna sintetasa ortogonales. |
US7085923B2 (en) | 2001-06-05 | 2006-08-01 | International Business Machines Corporation | High volume secure internet server |
EP1572885A2 (en) * | 2001-08-08 | 2005-09-14 | Genzyme Corporation | Methods for treating diabetes and other blood sugar disorders |
MXPA04001560A (es) | 2001-08-28 | 2004-05-17 | Lilly Co Eli | Premezclas de glp-1 e insulina basal. |
GB0121709D0 (en) * | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
US7041646B2 (en) * | 2001-10-05 | 2006-05-09 | Bayer Pharmaceuticals Corporation | Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists |
AR036711A1 (es) * | 2001-10-05 | 2004-09-29 | Bayer Corp | Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico |
RU2353625C2 (ru) * | 2001-10-18 | 2009-04-27 | Бристол-Маерс Сквибб Компани | Миметики человеческого глюканоподобного пептида-1 и их применение в лечении диабета и родственных состояний |
US20050014679A1 (en) | 2001-12-20 | 2005-01-20 | Beals John Michael | Insulin molecule having protracted time action |
JP2005518408A (ja) * | 2001-12-29 | 2005-06-23 | ノボ ノルディスク アクティーゼルスカブ | 異常脂肪血症を治療するための、glp−1化合物と他の薬物との組み合わせ使用 |
IL163666A0 (en) | 2002-02-22 | 2005-12-18 | New River Pharmaceuticals Inc | Active agent delivery systems and methods for protecting and administering active agents |
US20060252916A1 (en) * | 2002-06-04 | 2006-11-09 | Eli Lilly And Company | Modified glucagon-like peptide-1 analogs |
FR2842209B1 (fr) | 2002-07-09 | 2007-11-23 | Nouvelle protease aspartique dite saspase et son utilisation dans le domaine cosmetique et therapeutique | |
US7192922B2 (en) * | 2002-11-19 | 2007-03-20 | Allegheny-Singer Research Institute | Method of treating left ventricular dysfunction |
US20050059605A1 (en) | 2003-01-31 | 2005-03-17 | Krishna Peri | Chemically modified metabolites of regulatory peptides and methods of producing and using same |
WO2004078777A2 (en) | 2003-03-04 | 2004-09-16 | Biorexis Pharmaceutical Corporation | Dipeptidyl-peptidase protected proteins |
JP2006520818A (ja) * | 2003-03-19 | 2006-09-14 | イーライ リリー アンド カンパニー | ポリエチレングリコール結合glp−1化合物 |
ES2512499T3 (es) * | 2003-04-08 | 2014-10-24 | Yeda Research And Development Co., Ltd. | Fármacos pegilados reversibles |
GB0310593D0 (en) | 2003-05-08 | 2003-06-11 | Leuven K U Res & Dev | Peptidic prodrugs |
CN1802386B (zh) * | 2003-06-12 | 2010-12-15 | 伊莱利利公司 | Glp-1类似物融合蛋白质 |
WO2004111078A2 (en) * | 2003-06-18 | 2004-12-23 | Theratechnologies Inc. | Compounds that modulate the glucagon response and uses thereof |
PE20050948A1 (es) | 2003-09-09 | 2005-12-16 | Japan Tobacco Inc | Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv |
CN100444898C (zh) * | 2003-09-19 | 2008-12-24 | 诺沃挪第克公司 | 治疗肽的清蛋白结合型衍生物 |
BRPI0414539B8 (pt) * | 2003-09-19 | 2021-05-25 | Novo Nordisk As | composto, composição farmacêutica, e, uso de um composto |
WO2005035003A2 (en) | 2003-09-22 | 2005-04-21 | Dihedron Corporation | Compositions and methods for increasing drug efficiency |
US7364875B2 (en) * | 2003-10-30 | 2008-04-29 | Cresent Innovations, Inc. | Method for producing medical and commercial grade poly-gamma-glutamic acid of high molecular weight |
CN1906209A (zh) | 2003-11-05 | 2007-01-31 | 达纳-法伯癌症研究所股份有限公司 | 稳定的α螺旋肽及其用途 |
ATE517119T1 (de) | 2003-12-03 | 2011-08-15 | Novo Nordisk As | Einzelketteninsulin |
US7028106B2 (en) | 2003-12-05 | 2006-04-11 | Hewlett-Packard Development Company, L.P. | Remapping routing information entries in an expander |
BRPI0417717A (pt) * | 2003-12-18 | 2007-04-03 | Novo Nordisk As | composto, composição farmacêutica, e, uso de um composto |
US20060286129A1 (en) * | 2003-12-19 | 2006-12-21 | Emisphere Technologies, Inc. | Oral GLP-1 formulations |
US20080318837A1 (en) * | 2003-12-26 | 2008-12-25 | Nastech Pharmaceutical Company Inc. | Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide |
US20080139481A1 (en) * | 2004-06-17 | 2008-06-12 | Dix Thomas A | Non-Natural Amino Acids |
JP2008517917A (ja) | 2004-10-21 | 2008-05-29 | アイジーエフ オンコロジー エルエルシー | 癌を治療するための毒素および放射性核種結合igf−1受容体リガンド |
US8263545B2 (en) | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
SG159551A1 (en) * | 2005-02-11 | 2010-03-30 | Amylin Pharmaceuticals Inc | Gip analog and hybrid polypeptides with selectable properties |
US20090062192A1 (en) * | 2005-03-18 | 2009-03-05 | Novo Nordisk A/S | Dimeric Peptide Agonists of the Glp-1 Receptor |
JP2008533100A (ja) | 2005-03-18 | 2008-08-21 | ノボ ノルディスク アクティーゼルスカブ | Peg化された単鎖インスリン |
US7521211B2 (en) | 2005-04-05 | 2009-04-21 | Regeneron Pharmaceuticals, Inc | IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof |
US20090209453A1 (en) | 2005-04-13 | 2009-08-20 | University Of Medicine And Dentistry Of New Jersey | Glycoprotein Hormone Analogs |
WO2007030577A2 (en) | 2005-09-08 | 2007-03-15 | Shire Llc | Prodrugs of t3 and t4 with enhanced bioavailability |
ES2572952T3 (es) * | 2005-11-07 | 2016-06-03 | Indiana University Research And Technology Corporation | Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas |
US8304386B2 (en) | 2006-02-03 | 2012-11-06 | Prolor Biotech, Inc. | Long-acting growth hormone and methods of producing same |
JP2009527526A (ja) | 2006-02-21 | 2009-07-30 | ノボ・ノルデイスク・エー/エス | 単鎖インスリンのアナログとその製薬的製剤 |
WO2007104786A1 (en) * | 2006-03-15 | 2007-09-20 | Novo Nordisk A/S | Mixtures of amylin and insulin |
WO2007109354A2 (en) | 2006-03-21 | 2007-09-27 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of using same |
EP2054437A2 (en) | 2006-08-07 | 2009-05-06 | Teva Biopharmaceuticals USA, Inc. | Albumin-insulin fusion proteins |
JP5399244B2 (ja) | 2006-08-17 | 2014-01-29 | アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー | 選択可能な特性を持つdpp−iv耐性gipハイブリッドポリペプチド |
CL2007002502A1 (es) | 2006-08-31 | 2008-05-30 | Hoffmann La Roche | Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer. |
EP2069396B1 (en) * | 2006-09-08 | 2015-10-21 | Ambrx, Inc. | Modified human plasma polypeptide or fc scaffolds and their uses |
DE102006052755A1 (de) | 2006-11-08 | 2008-05-15 | N-Zyme Biotec Gmbh | Michaelsysteme als Transglutaminaseinhibitoren |
WO2008086086A2 (en) * | 2007-01-05 | 2008-07-17 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological ph buffers |
US20090098130A1 (en) | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
CA2677932A1 (en) | 2007-02-15 | 2008-08-21 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
US7859468B2 (en) * | 2007-08-30 | 2010-12-28 | Research In Motion Limited | Mobile wireless communications device including a folded monopole multi-band antenna and related methods |
EP2036539A1 (en) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Stable formulations of amylin and its analogues |
EP2036923A1 (en) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Improved derivates of amylin |
MX2010004298A (es) * | 2007-10-30 | 2010-05-03 | Univ Indiana Res & Tech Corp | Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1. |
MX338336B (es) | 2007-11-20 | 2016-04-07 | Ambrx Inc | Polipeptidos de insulina modificados y sus usos. |
WO2009099763A1 (en) | 2008-01-30 | 2009-08-13 | Indiana University Research And Technology Corporation | Ester-based peptide prodrugs |
US8906847B2 (en) | 2008-02-01 | 2014-12-09 | Ascendis Pharma A/S | Prodrug comprising a drug linker conjugate |
PE20100255A1 (es) * | 2008-06-17 | 2010-04-25 | Univ Indiana Res & Tech Corp | Co-agonistas del receptor de glucagon/glp-1 |
US8450270B2 (en) * | 2008-06-17 | 2013-05-28 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers |
CN102105159B (zh) * | 2008-06-17 | 2015-07-08 | 印第安纳大学研究及科技有限公司 | 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症 |
EP2356139A4 (en) | 2008-07-23 | 2013-01-09 | Harvard College | LIGATURE OF STAPLED POLYPEPTIDES |
BRPI0922969A2 (pt) | 2008-12-19 | 2019-09-24 | Univ Indiana Res & Tech Corp | pró-farmaco de amida baseado na superfamília de glucagon peptídeo. |
AU2009335711A1 (en) | 2008-12-19 | 2010-07-15 | Indiana University Research And Technology Corporation | Dipeptide linked medicinal agents |
EP2376521B1 (en) | 2008-12-19 | 2016-04-13 | Indiana University Research and Technology Corporation | Amide-based insulin prodrugs |
CN102256992B (zh) | 2008-12-19 | 2015-04-22 | 印第安纳大学研究及科技有限公司 | 胰岛素类似物 |
EP2408470A4 (en) | 2009-03-20 | 2012-08-29 | Smartcells Inc | SOLUBLE NONDEPOT INSULIN CONJUGATE AND ITS USE |
WO2011159895A2 (en) | 2010-06-16 | 2011-12-22 | Indiana University Research And Technology Corporation | Single chain insulin agonists exhibiting high activity at the insulin receptor |
RU2580317C2 (ru) | 2010-06-24 | 2016-04-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов |
WO2011163460A1 (en) | 2010-06-24 | 2011-12-29 | Indiana University Research And Technology Corporation | Yl-based insulin-like growth factors exhibiting high activity at the insulin receptor |
JP5912112B2 (ja) | 2010-06-24 | 2016-04-27 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | アミド系インスリンプロドラッグ |
-
2009
- 2009-01-21 WO PCT/US2009/031593 patent/WO2009099763A1/en active Application Filing
- 2009-01-21 CN CN200980112047.4A patent/CN101983066B/zh not_active Expired - Fee Related
- 2009-01-21 US US12/865,058 patent/US20110065633A1/en not_active Abandoned
- 2009-01-21 EP EP09708686A patent/EP2249853A4/en not_active Withdrawn
- 2009-01-21 CA CA2713348A patent/CA2713348C/en not_active Expired - Fee Related
- 2009-01-21 AU AU2009210570A patent/AU2009210570B2/en not_active Ceased
- 2009-01-21 JP JP2010545058A patent/JP2011511778A/ja active Pending
- 2009-01-23 TW TW098103051A patent/TW200938225A/zh unknown
- 2009-01-29 PE PE2009000119A patent/PE20091440A1/es not_active Application Discontinuation
- 2009-01-29 PA PA20098814001A patent/PA8814001A1/es unknown
- 2009-01-30 AR ARP090100301A patent/AR073335A1/es unknown
- 2009-01-30 CL CL2009000202A patent/CL2009000202A1/es unknown
-
2010
- 2010-07-28 US US12/845,455 patent/US8697838B2/en not_active Expired - Fee Related
-
2014
- 2014-02-18 US US14/182,706 patent/US9089539B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20100331246A1 (en) | 2010-12-30 |
US8697838B2 (en) | 2014-04-15 |
AU2009210570B2 (en) | 2014-11-20 |
CA2713348A1 (en) | 2009-08-13 |
US20110065633A1 (en) | 2011-03-17 |
CN101983066A (zh) | 2011-03-02 |
TW200938225A (en) | 2009-09-16 |
JP2011511778A (ja) | 2011-04-14 |
US9089539B2 (en) | 2015-07-28 |
CA2713348C (en) | 2018-10-09 |
AU2009210570A1 (en) | 2009-08-13 |
AR073335A1 (es) | 2010-11-03 |
PE20091440A1 (es) | 2009-09-20 |
CN101983066B (zh) | 2016-06-29 |
WO2009099763A1 (en) | 2009-08-13 |
CL2009000202A1 (es) | 2009-05-22 |
EP2249853A1 (en) | 2010-11-17 |
EP2249853A4 (en) | 2012-12-26 |
US20140212419A1 (en) | 2014-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PA8814001A1 (es) | Profármacos de péptidos basados en ésteres | |
ES2616658T3 (es) | Péptidos que mimetizan el factor de crecimiento y sus usos | |
ES2512141T3 (es) | Análogo peptídico de oxintomodulina | |
WO2010009277A3 (en) | Immunogenic amphipathic peptide compositions | |
WO2009029847A8 (en) | Compositions and methods of using proislet peptides and analogs thereof | |
BR122021020829B8 (pt) | Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada | |
WO2009022154A3 (en) | Peptide with multiple epitopes | |
WO2010009065A3 (en) | Amphipathic peptide compositions | |
EA200802170A1 (ru) | Лиофилизированная композиция терапевтического пептидного антитела | |
BRPI0606687A2 (pt) | composições nutracêuticas | |
NZ596658A (en) | Dig-10 insecticidal cry toxins | |
TW200708193A (en) | Vertical pixel structure for emi-flective display and method for making the same | |
SG178797A1 (en) | Oligosaccharide chain added glp-1 peptide | |
EA201190281A1 (ru) | Высоконадежные проглатываемые отметчики режима и способы их применения | |
WO2009002456A3 (en) | Methods and compositions relating to progenitor cells | |
BR112012014082A2 (pt) | composições e métodos que compreendem variantes de protease | |
BR112012026379A2 (pt) | métodos para gerar proteína endogenamente marcada | |
EA200901365A1 (ru) | Стабилизированная фармацевтическая композиция, содержащая прегабалин | |
WO2010048275A3 (en) | Lyophilized recombinant vwf formulations | |
WO2009007714A3 (en) | Human pancreatic polypeptide (hpp) analogues and their effects on feeding behaviour | |
CL2011002958A1 (es) | Composición que comprende ácido 4-oxo-4-[(2-feniletil)amino]-butírico y tolclofos-metilo; y método para controlar enfermedades en plantas. | |
WO2008157304A3 (en) | Stabilized thrombin compositions | |
TW200746885A (en) | Hot-melt type member and organic EL display panel | |
BRPI0518853A2 (pt) | estabilizaÇço de Ésteres de glicocorticàides com Ácidos | |
MX2014011614A (es) | Fragmentos y proteinas nutritivas con fenilalanina baja o nula y metodos. |